With this in mind, we sought to investigate the activity of MtCK in the serum of PD patients and controls with the hope that this would allow us to identify a potential biomarker for early diagnosis or progression of PD patients, as well as provide some avenues for further research regarding mitochondrial dysfunction in idiopathic PD. This evidence concerns the gene CKMT2 and Parkinson disease.